Clinical Trials
10 trialsNCT00880061 2018-07-05
An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00024570 2014-11-14
Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
INSYS Therapeutics Inc
Phase 1/2 Completed
NCT00378235 2014-11-13
Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma
INSYS Therapeutics Inc
Phase 1/2 Withdrawn
NCT00036972 2013-06-26
Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00006268 2013-06-24
Immunotoxin Therapy in Treating Patients With Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00089427 2011-07-04
IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
INSYS Therapeutics Inc
Phase 1 Completed
NCT00024557 2011-06-06
Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
INSYS Therapeutics Inc
Phase 1 Completed
NCT00041587 2011-06-06
Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
INSYS Therapeutics Inc
Phase 1/2 Completed
NCT00064779 2011-06-06
Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
INSYS Therapeutics Inc
Phase 1 Completed
NCT00076986 2011-06-06
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
INSYS Therapeutics Inc
Phase 3 Completed